| pubmed-article:6556071 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:6556071 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:6556071 | lifeskim:mentions | umls-concept:C1704675 | lld:lifeskim |
| pubmed-article:6556071 | lifeskim:mentions | umls-concept:C0023693 | lld:lifeskim |
| pubmed-article:6556071 | lifeskim:mentions | umls-concept:C1524075 | lld:lifeskim |
| pubmed-article:6556071 | lifeskim:mentions | umls-concept:C0313532 | lld:lifeskim |
| pubmed-article:6556071 | lifeskim:mentions | umls-concept:C2366367 | lld:lifeskim |
| pubmed-article:6556071 | lifeskim:mentions | umls-concept:C0337112 | lld:lifeskim |
| pubmed-article:6556071 | pubmed:issue | 20 | lld:pubmed |
| pubmed-article:6556071 | pubmed:dateCreated | 1983-12-20 | lld:pubmed |
| pubmed-article:6556071 | pubmed:abstractText | The light chain of human plasma kallikrein contains the enzymatic active site. The inactivation of kallikrein and of its isolated light chain by C1 inhibitor was investigated to assess the functional contributions of the heavy-chain region of kallikrein and of high molecular weight kininogen to this reaction. The second-order rate constants for the inactivation of kallikrein or its light chain were respectively 2.7 X 10(6) and 4.0 X 10(6) M -1 min -1. High molecular weight kininogen did not influence the rate of kallikrein inactivation. The nature of the complexes formed between kallikrein or its light chain and C1 inhibitor was studied by using sodium dodecyl sulfate (SDS) gradient polyacrylamide slab gel electrophoresis. Kallikrein as well as its light chain combined with C1 inhibitor to form stable stoichiometric complexes that were not dissociated by SDS and that exhibited apparent molecular weights (Mr's) of 185 000 and 135 000, respectively, on nonreduced SDS gels. Reduction of the kallikrein-C1 inhibitor complex gave a band at Mr 135 000 that comigrated with the complex seen for the light chain-C1 inhibitor complex. During the inactivation of both kallikrein and its light chain, a Mr 94 000 fragment of C1 inhibitor was formed which was unable to inactivate or bind kallikrein or its light chain. Kallikrein inactivated by diisopropyl phosphofluoridate did not form SDS-stable complexes with C1 inhibitor. These results demonstrate that the functional binding site for C1 inhibitor is localized in the light chain of kallikrein.(ABSTRACT TRUNCATED AT 250 WORDS) | lld:pubmed |
| pubmed-article:6556071 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6556071 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6556071 | pubmed:language | eng | lld:pubmed |
| pubmed-article:6556071 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6556071 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:6556071 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6556071 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6556071 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6556071 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6556071 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:6556071 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:6556071 | pubmed:issn | 0006-2960 | lld:pubmed |
| pubmed-article:6556071 | pubmed:author | pubmed-author:BoumaB NBN | lld:pubmed |
| pubmed-article:6556071 | pubmed:author | pubmed-author:GriffinJ HJH | lld:pubmed |
| pubmed-article:6556071 | pubmed:author | pubmed-author:KoedamJ AJA | lld:pubmed |
| pubmed-article:6556071 | pubmed:author | pubmed-author:van der... | lld:pubmed |
| pubmed-article:6556071 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:6556071 | pubmed:day | 27 | lld:pubmed |
| pubmed-article:6556071 | pubmed:volume | 22 | lld:pubmed |
| pubmed-article:6556071 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:6556071 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:6556071 | pubmed:pagination | 4860-6 | lld:pubmed |
| pubmed-article:6556071 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:6556071 | pubmed:meshHeading | pubmed-meshheading:6556071-... | lld:pubmed |
| pubmed-article:6556071 | pubmed:meshHeading | pubmed-meshheading:6556071-... | lld:pubmed |
| pubmed-article:6556071 | pubmed:meshHeading | pubmed-meshheading:6556071-... | lld:pubmed |
| pubmed-article:6556071 | pubmed:meshHeading | pubmed-meshheading:6556071-... | lld:pubmed |
| pubmed-article:6556071 | pubmed:meshHeading | pubmed-meshheading:6556071-... | lld:pubmed |
| pubmed-article:6556071 | pubmed:meshHeading | pubmed-meshheading:6556071-... | lld:pubmed |
| pubmed-article:6556071 | pubmed:meshHeading | pubmed-meshheading:6556071-... | lld:pubmed |
| pubmed-article:6556071 | pubmed:meshHeading | pubmed-meshheading:6556071-... | lld:pubmed |
| pubmed-article:6556071 | pubmed:year | 1983 | lld:pubmed |
| pubmed-article:6556071 | pubmed:articleTitle | Interaction of human plasma kallikrein and its light chain with C1 inhibitor. | lld:pubmed |
| pubmed-article:6556071 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:6556071 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:6556071 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6556071 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6556071 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6556071 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6556071 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6556071 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6556071 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6556071 | lld:pubmed |
